1887

Abstract

Carbapenems such as imipenem and meropenem are first-line agents for the treatment of serious nosocomial infections caused by multidrug-resistant clinical isolates of bacteria belonging to the family . However, resistance to carbapenems has increased dramatically among members of the family isolated from a teaching hospital in Shanghai, China. In the present study, we investigated the prevalence and molecular characteristics of carbapenem-resistant clinical isolates of . None of the 77 clinical isolates collected from 2002 to 2009 were susceptible to ertapenem and only 6.5 % and 1.3 % of isolates were susceptible to imipenem and meropenem, respectively. Colistin and tigecycline were found to be the most active agents against carbapenem-resistant isolates, inhibiting 90 % of isolates at a concentration of 1 µg ml and 4 µg ml, respectively. The results of PFGE analysis suggested that many of the KPC-2-producing isolates of and were clonally related. Most of these isolates were isolated from the same ward, namely the neurosurgical ward, suggesting horizontal transfer of the KPC-2-encoding gene in these isolates. Of the 77 isolates, 84.4 % were found, by PCR, to be capable of carbapenemase production. SDS-PAGE analysis revealed that 75.3 % (58/77) of the isolates had lost at least one porin protein. Our results suggested that the prompt detection of carbapenemase-producing strains is critical for the containment of nosocomial transmission. As no novel antimicrobials have been identified for use in the treatment of these pan-drug-resistant isolates, further studies should focus on the rational use of available antibiotics, the implementation of active antibiotic resistance surveillance and the strict implementation of infection control measures to avoid the rapid spread or outbreak of carbapenemase-producing in health-care facilities.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.036483-0
2012-01-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/1/132.html?itemId=/content/journal/jmm/10.1099/jmm.0.036483-0&mimeType=html&fmt=ahah

References

  1. Bratu S., Tolaney P., Karumudi U., Quale J., Mooty M., Nichani S., Landman D. 2005; Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 56:128–132 [View Article][PubMed]
    [Google Scholar]
  2. Brink A. J., Feldman C., Grolman D. C., Muckart D., Pretorius J., Richards G. A., Senekal M., Sieling W. 2004; Appropriate use of the carbapenems. S Afr Med J 94:857–861[PubMed]
    [Google Scholar]
  3. Carvalhaes C. G., Picão R. C., Nicoletti A. G., Xavier D. E., Gales A. C. 2010; Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results. J Antimicrob Chemother 65:249–251 [View Article][PubMed]
    [Google Scholar]
  4. CDC 2009; Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 58:256–260
    [Google Scholar]
  5. Chen Y., Zhou Z., Jiang Y., Yu Y. 2011; Emergence of NDM-1-producing Acinetobacter baumannii in China. J Antimicrob Chemother 66:1255–1259 [View Article][PubMed]
    [Google Scholar]
  6. CLSI 2010; Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement. M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute;
  7. EUCAST 2011; Breakpoint tables for interpretation of MICs and zone diameters (version 1.3, January 5, 2011). http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf
  8. Girlich D., Poirel L., Nordmann P. 2009; CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli . Antimicrob Agents Chemother 53:832–834 [View Article][PubMed]
    [Google Scholar]
  9. Gootz T. D., Lescoe M. K., Dib-Hajj F., Dougherty B. A., He W., Della-Latta P., Huard R. C. 2009; Genetic organization of transposase regions surrounding bla KPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. Antimicrob Agents Chemother 53:1998–2004 [View Article][PubMed]
    [Google Scholar]
  10. Hirsch E. B., Tam V. H. 2010; Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65:1119–1125 [View Article][PubMed]
    [Google Scholar]
  11. Hosaka M., Gotoh N., Nishino T. 1995; Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ. Antimicrob Agents Chemother 39:1731–1735[PubMed] [CrossRef]
    [Google Scholar]
  12. Hunter S. B., Vauterin P., Lambert-Fair M. A., Van Duyne M. S., Kubota K., Graves L., Wrigley D., Barrett T., Ribot E. 2005; Establishment of a universal size standard strain for use with the PulseNet standardized pulsed-field gel electrophoresis protocols: converting the national databases to the new size standard. J Clin Microbiol 43:1045–1050 [View Article][PubMed]
    [Google Scholar]
  13. Jacoby G. A., Mills D. M., Chow N. 2004; Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae . Antimicrob Agents Chemother 48:3203–3206 [View Article][PubMed]
    [Google Scholar]
  14. Kumarasamy K. K., Toleman M. A., Walsh T. R., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske C. G. other authors 2010; Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10:597–602 [View Article][PubMed]
    [Google Scholar]
  15. Lee K., Lim Y. S., Yong D., Yum J. H., Chong Y. 2003; Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp.. J Clin Microbiol 41:4623–4629 [View Article][PubMed]
    [Google Scholar]
  16. Munoz-Price L. S., Quinn J. P. 2009; The spread of Klebsiella pneumoniae carbapenemases: a tale of strains, plasmids, and transposons. Clin Infect Dis 49:1739–1741 [View Article][PubMed]
    [Google Scholar]
  17. Murray P. R., Baron E. J., Jorgensen J. H., Landry M. L., Pfaller M. A. 2007; Detection and characterization of antimicrobial resistance genes in pathogenic bacteria. In Manual of Clinical Microbiology, 9th edn. pp. 1250–1256 Edited by Rasheed J. K., Cockerill F., Tenover F. C. Washington, DC: American Society for Microbiology;
    [Google Scholar]
  18. Peleg A. Y., Hooper D. C. 2010; Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med 362:1804–1813 [View Article][PubMed]
    [Google Scholar]
  19. Pliatsika V., Afkou Z., Protonotariou E., Sofianou D. 2007; In vitro activity of tigecycline against metallo-β-lactamase-producing Enterobacteriaceae . J Antimicrob Chemother 60:1406–1407 [View Article][PubMed]
    [Google Scholar]
  20. Pournaras S., Protonotariou E., Voulgari E., Kristo I., Dimitroulia E., Vitti D., Tsalidou M., Maniatis A. N., Tsakris A., Sofianou D. 2009; Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 64:348–352 [View Article][PubMed]
    [Google Scholar]
  21. Pournaras S., Poulou A., Tsakris A. 2010; Inhibitor-based methods for the detection of KPC carbapenemase-producing Enterobacteriaceae in clinical practice by using boronic acid compounds. J Antimicrob Chemother 65:1319–1321 [View Article][PubMed]
    [Google Scholar]
  22. Queenan A. M., Bush K. 2007; Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440–458 [View Article][PubMed]
    [Google Scholar]
  23. Rolain J. M., Parola P., Cornaglia G. 2010; New Delhi metallo-β-lactamase (NDM-1): towards a new pandemia?. Clin Microbiol Infect 16:1699–1701 [View Article][PubMed]
    [Google Scholar]
  24. Schwaber M. J., Carmeli Y. 2008; Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 300:2911–2913 [View Article][PubMed]
    [Google Scholar]
  25. Sidjabat H. E., Silveira F. P., Potoski B. A., Abu-Elmagd K. M., Adams-Haduch J. M., Paterson D. L., Doi Y. 2009; Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 49:1736–1738 [View Article][PubMed]
    [Google Scholar]
  26. Tenover F. C., Arbeit R. D., Goering R. V., Mickelsen P. A., Murray B. E., Persing D. H., Swaminathan B. 1995; Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239[PubMed]
    [Google Scholar]
  27. Walsh T. R., Toleman M. A., Poirel L., Nordmann P. 2005; Metallo-β-lactamases: the quiet before the storm?. Clin Microbiol Rev 18:306–325 [View Article][PubMed]
    [Google Scholar]
  28. Woodford N., Tierno P. M. Jr, Young K., Tysall L., Palepou M. F. I., Ward E., Painter R. E., Suber D. F., Shungu D. other authors 2004; Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 48:4793–4799 [View Article][PubMed]
    [Google Scholar]
  29. Yigit H., Queenan A. M., Anderson G. J., Domenech-Sanchez A., Biddle J. W., Steward C. D., Alberti S., Bush K., Tenover F. C. 2001; Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae . Antimicrob Agents Chemother 45:1151–1161 [View Article][PubMed]
    [Google Scholar]
  30. Zhu D., Zhang Y., Wang F. 2006; Surveillance of bacterial resistance in Shanghai hospitals during 2006. Chin J Infect Chemother 7:393–399 [CrossRef]
    [Google Scholar]
  31. Zhu D., Zhang Y., Wang F. 2007; Surveillance of bacterial resistance from hospitals in Shanghai in 2007. Chin J Infect Chemother 8:401–410
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.036483-0
Loading
/content/journal/jmm/10.1099/jmm.0.036483-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error